Benjamin Chastek
Overview
Explore the profile of Benjamin Chastek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
432
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lv L, Rajpura J, Liu M, Strum M, Chastek B, Johnson J, et al.
Am J Prev Cardiol
. 2025 Mar;
21:100950.
PMID: 40060171
Background: Systemic inflammation (SI) is a risk factor for atherosclerotic cardiovascular disease (ASCVD) and is most commonly assessed by measuring levels of high-sensitivity C-reactive protein (hsCRP). Objective: This study aimed...
2.
Krugliak Cleveland N, Ghosh S, Chastek B, Bancroft T, Candela N, Fan T, et al.
BMC Gastroenterol
. 2024 Sep;
24(1):314.
PMID: 39289603
Background: Patients with inflammatory bowel disease (IBD) are at risk of developing dysplasia and, subsequently, colorectal cancer (CRC) owing to chronic inflammation. Patients may also experience other severe disease complications,...
3.
Swami U, Hong A, Diessner B, Young C, Bunner S, Xie B, et al.
Future Oncol
. 2024 Jul;
20(32):2467-2480.
PMID: 39073610
Androgen receptor pathway inhibitors (ARPIs) prolong metastasis-free survival and overall survival in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). This study aimed to evaluate real-world treatment patterns, utilization and survival...
4.
McGovern I, Chastek B, Bancroft T, Webb N, Imran M, Pelton S, et al.
Int J Infect Dis
. 2024 Jul;
146:107160.
PMID: 38969330
Objectives: This study evaluated relative vaccine effectiveness (rVE) of MF59-adjuvanted trivalent inactivated influenza vaccine (aTIV) vs high-dose trivalent inactivated influenza vaccine (HD-TIV) for prevention of test-confirmed influenza emergency department visits...
5.
Bell C, Wu B, Huang S, Rubin B, Averell C, Chastek B, et al.
BMC Health Serv Res
. 2024 May;
24(1):691.
PMID: 38822336
Background: We aimed to describe healthcare resource utilization (HCRU) and healthcare costs in patients with newly confirmed lupus nephritis (LN) in the United States over a 5-year follow-up period. Methods:...
6.
Chastek B, Carrera A, Landis C, Snyder D, Abedinzadeh L, Bancroft T, et al.
Neurourol Urodyn
. 2024 May;
43(7):1504-1513.
PMID: 38720543
Introduction: Vibegron is a selective β-adrenergic receptor agonist that was approved by the US Food and Drug Administration in December 2020 for the treatment of overactive bladder in adults. This...
7.
Silver J, Steffens A, Chastek B, Deb A
J Asthma Allergy
. 2024 Mar;
17:261-271.
PMID: 38544676
Purpose: Real-world data on mepolizumab in patients with severe asthma and allergic and non-allergic phenotypes are limited. This study investigated the effectiveness of mepolizumab treatment in patients with severe asthma...
8.
Chastek B, Carrera A, Landis C, Snyder D, Abedinzadeh L, Bancroft T, et al.
Adv Ther
. 2024 Mar;
41(5):2086-2097.
PMID: 38520502
Introduction: Vibegron is a β-adrenergic receptor agonist approved for overactive bladder (OAB). This analysis assessed real-world adherence and persistence with vibegron in patients with OAB, along with demographics and clinical...
9.
Krugliak Cleveland N, Ghosh S, Chastek B, Bancroft T, Candela N, Fan T, et al.
Inflamm Bowel Dis
. 2023 Nov;
30(10):1776-1787.
PMID: 37921344
Background: Patients with inflammatory bowel disease (IBD) may receive multiple successive biologic treatments in clinical practice; however, data are limited on the comparative effectiveness of biologics and the impact of...
10.
Singer D, Chastek B, Sargent A, Johnson J, Shetty S, Conoscenti C, et al.
BMC Pulm Med
. 2023 Sep;
23(1):337.
PMID: 37689630
Background: Many types of interstitial lung diseases (ILDs) may transition to progressive chronic-fibrosing ILDs with rapid lung function decline and a negative survival prognosis. In real-world clinical settings, forced vital...